TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24796463
Drug: Trastuzumab administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab administered sequentially with anthracycline
Study: 18771049
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice daily of Phase III formulation
Study: 18771049
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice daily of Phase III formulation
Study: 18771049
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg twice daily of Phase II formulation
Study: 12176916
Drug: Intravenous cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclosporin A (CsA)
Study: 10207508
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration (i.v. GH bolus)
Study: 10207508
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion with GH administration
Study: 10207508
Drug: Insulin induced
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin induced hypoglycemia in GH-deficient patients
Study: 7598298
Drug: Twice-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly regimen of sulfadiazine (500 mg four times per day) plus pyrimethamine (25 mg) plus folinic acid (15 mg)
Study: 7598298
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen of sulfadiazine (500 mg four times per day) plus pyrimethamine (25 mg) plus folinic acid (15 mg)
Study: 28986029
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen
Study: 2184706
Drug: Topical TAC
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TAC (0.5% tetracaine, 1:2,000 adrenalin, 11.8% cocaine)
Study: 11188564
Drug: Intradermal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal lidocaine
Study: 30231866
Drug: Levothyroxine 25
Normalized name: LEVOTHYROXINE 25MCG/ML ORAL SOLN UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine 25 or 50 micrograms daily
Study: 10774589
Drug: Atevirdine (dose-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine (dose-adjusted to achieve plasma trough concentrations of 5-10 microM) and zidovudine (200 mg every 8 h) for 12 weeks (ACTG 199)
Study: 10774589
Drug: Atevirdine monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine monotherapy with doses adjusted to achieve targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM) for 12 weeks (ACTG 187)
Study: 6743720
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg/kg iv bolus infusion)
Study: 29424441
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg IV iron isomaltoside infusion
Study: 26710216
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg (group K)
Study: 23026514
Drug: High thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High thiamine diet (2.8 mg/day)
Study: 23026514
Drug: Adequate thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adequate thiamine diet (1.1 mg/day)
Study: 20040884
Drug: Musculoskeletal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musculoskeletal therapy and physical therapy prior to weight management program
Study: 12422590
Drug: Azithromycin 20
Normalized name: azithromycin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg/day for the first day followed by 10 mg/kg/day for a further four days
Study: 10028084
Drug: Clarithromycin plus
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin plus clofazimine with additional antimycobacterial drugs (ethambutol, ciprofloxacin, amikacin, rifabutin)
Study: 6616153
Drug: L-phenylalanine mustard
Normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-phenylalanine mustard (L-PAM) as adjuvant chemotherapy
Study: 6616153
Drug: Routine sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine sequential chest radiography
Study: 30906874
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment
Study: 25683747
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg glucose
Study: 25683747
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg glucose
Study: 24080099
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus supervised exercise therapy
Study: 16029398
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal ketamine (50 mg)
Study: 2068474
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aztreonam and cloxacillin/oxacillin
Study: 2068474
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tobramycin and a cephalosporin
Study: 6683538
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg calcium dobesilate
Study: 6683538
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg calcium dobesilate
Study: 6683538
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg calcium dobesilate
Study: 7760988
Drug: Minaprine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine (200 mg)
Study: 7760988
Drug: Imipramine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50, 75, 100 mg)
Study: 2397553
Drug: Modified Xiao‐Jin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Xiao‐Jin Pills (MXJP)
Study: 81155
Drug: Dihydrocodeine tartrate
Normalized name: Dihydrocodeine tartrate
DrugBank: Dihydrocodeine (DB01551)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydrocodeine tartrate (30 mg)
Study: 30833647
Drug: Capecitabine for
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine for 6 months (2500 mg/m2/day for 14 out of 21 days)
Study: 30833647
Drug: Capecitabine for
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine for 12 months (2500 mg/m2/day for 14 out of 21 days)
Study: 21837551
Drug: Process Assessment
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process Assessment of the Learner (PAL) lesson plans, specifically Lesson Sets 4 and 7, conducted via small groups (3-6 students) twice a week for 12 weeks.
Study: 9039714
Drug: Continuous and
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous and intermittent use of GTN patches
Study: 9039714
Drug: Changing to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changing to a different transdermal system
Study: 3882216
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment only (S-group)
Study: 24909206
Drug: Closed-loop therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop therapy with meal announcement
Study: 26072052
Drug: Conventional pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pump therapy
Study: 17391167
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and pioglitazone 30 mg daily
Study: 15713724
Drug: Oral Testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone (T) 200, 400, or 800 mg in sesame oil
Study: 15713724
Drug: Oral Testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone Enanthate (TE) 200, 400, or 800 mg in sesame oil
Study: 15713724
Drug: Oral Testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone (T) 200, 400, or 800 mg in sesame oil with Dutasteride (D)
Study: 15713724
Drug: Oral Testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone Enanthate (TE) 200, 400, or 800 mg in sesame oil with Dutasteride (D)
Study: 2111982
Drug: OKT3 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 monoclonal antibody (replacing cyclosporine during the first postoperative week)
Study: 2111982
Drug: Conventional immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppression (cyclosporine, azathioprine, and steroids)
Study: 25627152
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy
Study: 31728673
Drug: 2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day prednisone
Study: 31728673
Drug: 1.5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg/day prednisone
Study: 31728673
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day prednisone
Study: 31728673
Drug: Cumulative prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative prednisone dose for 1.5 mg/kg/day
Study: 31728673
Drug: Cumulative prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative prednisone dose for 1 mg/kg/day
Study: 31099599
Drug: MacConkey agar
Normalized name: Agar
Approvals — FDA: no, EMA: no, PMDA: no
Description: MacConkey agar medium supplemented with 8 mg/L of ceftiofur (MC-CEF)
Study: 20876366
Drug: Non-diuretic antihypertensive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-diuretic antihypertensive treatment (Control)
Study: 17202205
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy associated with systemic steroids (SS + PDT)
Study: 2886822
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose maintained at 3.2 mmol/l
Study: 20538327
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (defined as 25-hydroxyvitamin D level of 30 ng/mL or less)
Study: 17083064
Drug: Losartan (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50-100 mg/d)
Study: 1660550
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (5%, 10%, and 20% of the pressor dose)
Study: 11437859
Drug: Lisinopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (ACE inhibitor)
Study: 6751131
Drug: Abstinence-oriented insight
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence-oriented insight group therapy
Study: 6751131
Drug: Controlled drinking-oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled drinking-oriented behavioral modification group therapy
Study: 11914029
Drug: rhGH administration
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH administration
Study: 29886113
Drug: Intralesional verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional verapamil (2.5 mg/mL)
Study: 29886113
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (40 mg/mL)
Study: 26357940
Drug: AFN-1252 100
Normalized name: AFN-1252
DrugBank: AFN-1252 (DB12658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFN-1252 100 mg
Study: 23159479
Drug: 16 IU
Normalized name: QUATERNIUM-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 IU of intranasal oxytocin
Study: 25860107
Drug: Desvenlafaxine 50
Normalized name: desvenlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50 mg/day
Study: 16552801
Drug: 5'‐DFUR oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR oral administration at the dose of 800‐1200 mg/d for 3 ‐ 5 d
Study: 16552801
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg 5‐FU + 200 mg/d CF by venous drip for 3 ‐ 5 d
Study: 14586743
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (0.5 mg/kg per day of prednisolone)
Study: 10756223
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (as-needed usage)
Study: 1563463
Drug: Lisuride subcutaneous
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride subcutaneous infusion
Study: 3909544
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Acyclovir ointment and Oral acyclovir)
Study: 30284023
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and losartan combination therapy
Study: 19416259
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 microg mL(‐1) scalp solution - twice daily
Study: 18001533
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg + amlodipine + benazepril
Study: 9587047
Drug: Neoplanta capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoplanta capsule
Study: 9587047
Drug: Sandimmune Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune Neoral capsule
Study: 11125309
Drug: Zidovudine treatment
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine treatment
Study: 23136231
Drug: DD-MVAC (M
Approvals — FDA: no, EMA: no, PMDA: no
Description: DD-MVAC (M 30 mg/m(2), V 3 mg/m(2), A 30 mg/m(2), C 70 mg/m(2) q 2 weeks)
Study: 23136231
Drug: DD-GC (G
Approvals — FDA: no, EMA: no, PMDA: no
Description: DD-GC (G 2500 mg/m(2), C 70 mg/m(2) q 2 weeks)
Study: 22177374
Drug: Intravenous MID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous MID administration
Study: 22177374
Drug: Oral MID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MID administration
Study: 12622624
Drug: Narrowband UV-B
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband UV-B (TL-01) phototherapy 3 times weekly
Study: 12622624
Drug: Oral 8-methoxypsoralen
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 8-methoxypsoralen photochemotherapy (8-MOP PUVA) twice weekly
Study: 10954911
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon (5 x 10(6) U thrice weekly) plus vinblastine (6 mg/m2 every 14 days)
Study: 10954911
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon monotherapy (15 x 10(6) U thrice weekly)
Study: 9247766
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg and Losartan 50 mg
Study: 8325192
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of the same solution without Doppler investigation
Study: 3568582
Drug: beta-blockade (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blockade (2 X 80 mg oral propranolol per day)
Study: 29979799
Drug: Continuous Cryotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Cryotherapy (CC)
Study: 27632270
Drug: Nonsplinted implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsplinted implants
Study: 15945304
Drug: Splinted implants
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Splinted implants
Study: 7453623
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine A/Brazil/11/78
Study: 26535968
Drug: 10, 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 20, 30, or 40 mg hydrocodone-ER (single dose)
Study: 26535968
Drug: hydrocodone-ER (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocodone-ER (single and multiple doses)
Study: 17414929
Drug: FTC/TDF (200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TDF (200/300 mg once daily) for 7 days followed by GS-9137/r (50/100 mg once daily) and GS-9137/r plus FTC/TDF in a crossover fashion for 10 days.
Study: 17414929
Drug: GS-9137/r (50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9137/r (50/100 mg once daily) alone.
Study: 15384797
Drug: Once-weekly mupirocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly mupirocin application (n = 18; men/women: 10/8; age: 55.3 ± 1.8 years)
Study: 10511404
Drug: Ceftazidime i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime i.v. (1 g tid) + netilmicin i.v. (2 mg/kg bodyweight tid)
Study: 10511404
Drug: Cefotaxime i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime i.v. (2 g tid) + netilmicin i.v. (2 mg/kg bodyweight tid)
Study: 2037703
Drug: Guanfacine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine, 1 mg every night
Study: 2037703
Drug: Methyldopa, 250
Normalized name: Methyldopa, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa, 250 mg tid
Study: 31287757
Drug: Endovascular Treatment
Normalized name: Drug coated peripheral artery endovascular stent graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Treatment (EVT) for M2 occlusions
Study: 31287757
Drug: Endovascular Treatment
Normalized name: Drug coated peripheral artery endovascular stent graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Treatment (EVT) for dominant M2 occlusions
Study: 31287757
Drug: Endovascular Treatment
Normalized name: Drug coated peripheral artery endovascular stent graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Treatment (EVT) for nondominant M2 occlusions
Study: 31287757
Drug: Endovascular Treatment
Normalized name: Drug coated peripheral artery endovascular stent graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Treatment (EVT) for M1 occlusions
Study: 29567116
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 144/38.4, GFF MDI 18/9.6, GP MDI 144 μg
Study: 29567116
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 36/9.6, GP MDI 36, FF MDI 9.6 μg
Study: 29567116
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 144/38.4 μg
Study: 26864369
Drug: Egg intake
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg intake (1 additional egg (55 g)/d)
Study: 26864369
Drug: Cholesterol intake
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol intake (100 mg/d higher)
Study: 17937567
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily (q.d.) or 60 mg twice daily (b.i.d.)
Study: 3107660
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg at bedtime
Study: 8186350
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at bedtime
Study: 24849545
Drug: Mitotane as
Normalized name: Mitotane
DrugBank: Mitotane (DB00648)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitotane as a single agent
Study: 22333737
Drug: FISH (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FISH (group consuming fish 3-4 times weekly but avoiding meat and poultry)
Study: 22333737
Drug: OMN (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMN (control group consuming meat, fish, and poultry daily)
Study: 11688936
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein energy supplements (120 mL sip feed, 3 times daily, 540 kcal, 22.5 g protein per day)
Study: 11688936
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein energy supplements
Study: 23950156
Drug: Travoprost plus
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Travoprost plus timolol fixed combination (TTFC)
Study: 23950156
Drug: Latanoprost plus
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost plus timolol fixed combination (LTFC)
Study: 20582993
Drug: L-dopa/carbidopa/entacapone (LCE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/carbidopa/entacapone (LCE)
Study: 10097930
Drug: Repaglinide (0.5-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.5-4 mg t.i.d.)
Study: 10097930
Drug: Glyburide (1.75-10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (1.75-10.5 mg daily)
Study: 2129490
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment periods
Study: 1867965
Drug: Disopyramide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (150 mg racemic drug administered intravenously)